


REMARKS

Currently claims 1 to 52 are pending. Applicants amend the claims to reduce the filing fee by, *inter alia*, removing multiple dependency. Claims 2-4, 18, 20, 23-27, and 30-33 are cancelled without prejudice to reduce filing fees. Claims 49 and 50 are cancelled as being inappropriate to U.S. practice. Consequently claims 1, 5-17, 19, 21-22, 28-29, 34-48 and 51-52 are presented for examination. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,



John L. Lemanowicz
Attorney for Applicant
Registration No. 37,380

Date: July 15, 2004
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8247
Facsimile: 919-483-7988